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Prions are comprised principally of aggregates of a misfolded host protein and cause fatal
transmissible neurodegenerative disorders of mammals, such as variant Creutzfeldt–Jakob
disease in humans and bovine spongiform encephalopathy in cattle. Prions pose significant public
health concerns through contamination of blood products and surgical instruments, and can resist
conventional hospital sterilization methods. Prion infectivity binds avidly to surgical steel and can
efficiently transfer infectivity to a suitable host, and much research has been performed to achieve
effective prion decontamination of metal surfaces. Here, we exploit the highly sensitive Standard
Steel-Binding Assay (SSBA) to perform a direct comparison of a variety of commercially available
decontamination reagents marketed for the removal of prions, alongside conventional sterilization
methods. We demonstrate that the efficacy of marketed prion decontamination reagents is highly
variable and that the SSBA is able to rapidly evaluate current and future decontamination
reagents.
INTRODUCTION
Transmissible spongiform encephalopathies or prion diseases
are a closely related group of fatal neurodegenerative disorders
that affect the central nervous system (CNS) of mammals.
They include Creutzfeldt–Jakob disease (CJD), Gerstmann–
Stra ¨ussler–Scheinker disease, fatal familial insomnia and kuru
in humans, bovine spongiform encephalopathy (BSE) in cattle
and scrapie in sheep.
According to the protein-only hypothesis (Griffith, 1967)
the infectious agent, or prion, is composed of aggregated
forms of a non-native conformer of host-encoded cellular
prion protein (PrP
C), known as PrP
Sc (Prusiner, 1982;
Collinge, 2001). PrP
Sc is deposited in brain and lymphor-
eticular tissue as stable aggregates. Prions can be generated
sporadically, as a result of an as yet uncharacterized
stochastic event causing PrP
C to PrP
Sc conversion, or by
dominant mutations in the gene encoding PrP (PRNP in
humans), producing mutant PrP
C that is hypothesized to
more readily undergo spontaneous conversion to PrP
Sc.
However, uniquely among neurodegenerative disorders,
prion disease can also be caused through infection with
exogenous prions; the latter inducing host-encoded PrP
C
to undergo conformational change, via seeding or
template-directed refolding and hence replication and
spread (reviewed by Collinge & Clarke, 2007).
Classical (sporadic) CJD is rare with the infectious material
being largely confined to the tissues of the CNS (Wadsworth
et al., 2001; Glatzel et al., 2003; Head et al., 2004). Hence,
the risk of iatrogenic transmission from surgical instru-
ments has previously been considered to be relatively low.
However, recent epidemiological studies have suggested an
association between surgical treatment and sporadic CJD
(Collins et al., 1999; Mahillo-Fernandez et al., 2008; de
Pedro-Cuesta et al., 2010). In contrast, in variant CJD
(vCJD), PrP
Sc and infectivity have been shown to be
present in a wide variety of tissues throughout the body in
addition to the CNS, these include the lymphoreticular
system (spleen, tonsils and lymph nodes), components of
the eye and optic nerve, and in the gastrointestinal tract
(Wadsworth et al., 2001; Bruce et al., 2001; Head et al.,
2004; Joiner et al., 2005; Wadsworth et al., 2007; Notari
et al., 2010). Recent cases of transfusion-related vCJD
indicate that blood contains significant levels of infectivity
and suggests transfusion may be an efficient route of vCJD
transmission (Llewelyn et al., 2004; Peden et al., 2004;
Wroe et al., 2006; HPA Press Office, 2009). Treatment
with blood products is also a risk factor and a case of vCJD
prion infection has recently been reported in a haemophil-
iac (Peden et al., 2010). With such widespread distribution
of infectivity throughout the body many common surgical
procedures, such as abdominal surgery, tonsillectomy,
appendicectomy, gastrointestinal endoscopy and biopsy
may also pose a risk for iatrogenic transmission (Collins
et al., 1999; Hill et al., 1999; Wadsworth et al., 2001; Bruce
et al., 2001; Bramble & Ironside, 2002; Joiner et al., 2002;
Wadsworth et al., 2007).
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prevalence data for vCJD prion infection. A national
prevalence study was carried out to estimate the number of
people in the UK who are infected. Appendix material was
tested for the deposition of disease-associated PrP by
immunohistochemistry (Hilton et al., 2004). Three positive
samples were identified in a sample set of 12674 and the
authors estimated (95% confidence interval) between 49
and 692 people per million of the population may be
asymptomatic vCJD prion-infected carriers in the UK. An
extensive study of discarded tonsil specimens in the UK,
following on from an earlier pilot study (Frosh et al., 2004),
although negative, has not been able to narrow these
estimates by a major degree and further studies are in
progress (Clewley et al., 2009).
Prion infectivity has been shown to bind avidly to steel
surfaces and can effectively transmit disease to experi-
mental animals following even brief exposure to prion-
infected tissues (Zobeley et al., 1999; Flechsig et al., 2001).
Accidental transmission to humans via a contaminated
neurosurgical instrument has also been reported (Bernoulli
et al., 1977; Gibbs et al., 1994). Collectively, all prion
diseases raise the potential for surgical instruments to
become contaminated with prions during surgical proce-
dures (Davanipour et al., 1985; Collins et al., 1999;
Minatogawa & Kumoi, 1999; Ward et al., 2002; Mahillo-
Fernandez et al., 2008), including anaesthesia (Hernandez-
Palazon et al., 1998) and dentistry (Smith et al., 2002;
Walker et al., 2007).
It has long been established that prions are resistant to
conventional autoclaving as well as other sterilization
techniques such as exposure to both ionizing and UV
radiation and formalin treatment, which have been used
in hospital environments for non-autoclavable surgical
instruments (Taylor, 1991; Rutala & Weber, 2001; Fichet
et al., 2004). Effective destruction can be achieved by the
use of corrosive agents such as 2 M NaOH or 20% (v/v)
sodium hypochlorite (Prusiner et al., 1981; Taylor et al.,
1999). More recently, use of enzyme-based decontamina-
tion methods have shown to be equally effective (Fichet
et al., 2004; Jackson et al., 2005; Edgeworth et al., 2009)
with the advantage of being applicable to delicate surgical
instruments and medical devices that cannot be autoclaved,
as well as being far less hazardous to operators.
An independent study examining the efficacy of routine
decontamination of surgical instruments from hospitals
highlighted the high levels of residual protein remaining
on supposedly clean instruments (Murdoch et al., 2006).
Several studies have investigated the efficacy of combining
detergent preparations to aid general instrument cleaning
with and without the addition of enzymes as decontam-
ination reagents for prions from surgical steel wires (Yan
et al., 2004; Fichet et al., 2004; Jackson et al., 2005; Peretz
et al., 2006). This research led to the launch of pro-
ducts designed to reduce the risks of iatrogenic prion
transmission.
Here, we report on a comparative analysis of some of these
commercially available prion decontamination methods
using the in vitro Standard Steel-Binding Assay (SSBA)
(Edgeworth et al., 2009), which is an adaptation of the
Scrapie Cell Assay (Klohn et al., 2003) and is capable of
sensitively detecting metal-bound prion infectivity. The
assay has a large dynamic range (of ~6 logs) and is
approximately 100-fold more sensitive than conventional
rodent bioassay. It is capable of detecting infectivity in
brain homogenate diluted by up to 10
10-fold (Edgeworth
et al., 2009), thus allowing a direct comparison of the
efficacy of these reagents in decontaminating prion-
infected surgical steel surfaces.
RESULTS
Comparison of proteinase K (PK) digestion
kinetics of vCJD and RML (Rocky Mountain
Laboratory) prions
While validation of decontamination protocols using vCJD
prions would be preferable in principle, significant
transmission barriers preclude sensitive bioassay in
rodents, including humanized transgenic mice (Hill et al.,
1997; Asante et al., 2002). No cell line in which vCJD
prions can be efficiently propagated and assayed has yet
been reported. The N2aPK1 cell line used in the SSBA that
forms the basis of this study is highly susceptible to
infection with RML prions, one of the best characterized
and most widely used rodent-adapted prion strains (Klohn
et al., 2003). While RML prions seem highly suitable as a
model strain on this basis, it is important when considering
efficacy of decontamination reagents involving proteolysis
to ensure that the disease-associated PrP is not unusually
protease sensitive when compared to vCJD prions. We
measured the kinetics of proteolysis of both RML and
vCJD prion-infected brain homogenates by PK digestion
(Fig. 1a). It was observed that disease-associated PrP from
both RML and vCJD prion-infected brain homogenates
were degraded at two distinct rates by PK, indicating
the presence of at least two distinct subpopulations of
protease-resistant material. The slowly degraded, most
PK-resistant, fraction constituted more than 80% of the
material in an RML prion-infected brain, whereas this
fraction was the minority of material in human vCJD
prion-infected brain, where it comprised less than 47% of
the total. Additionally, the more resistant fraction asso-
ciated with the RML strain type was degraded at a slower
rate than the equivalent fraction associated with vCJD
(0.0004 s
21 compared with 0.0011 s
21), indicating a
greater resistance to degradation by PK (Table 1). While
these data do not directly determine the relative sensitiv-
ities of RML and vCJD prions to the formulations tested, it
does provide reassurance that RML PrP
Sc is not unusually
protease sensitive in comparison to that seen in vCJD. We
therefore considered RML prions to be a suitable model
strain to assess decontamination with proteolytic methods.
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decontamination reagents
These reagents were compared directly in the SSBA to
quantify any remaining infectivity bound to the metal
surface after treatment (Fig. 2). The most effective
commercially available decontamination reagents of those
tested were Rely
+On PI (Du Pont Corporation) and
Prionzyme (Genencor). Wires which were initially exposed
to a 10
2-fold dilution of RML prion-infected brain that
were subsequently treated with both reagents had their
residual infectivity reduced to below the detection limit of
0.0029 tissue culture infectious units on wires (TCIUw)
(equivalent to 10
210 dilution of RML-infected brain). Both
reagents decontaminate steel wires to a level beyond
detection by the SSBA and therefore a reduction of prion
infectivity of at least 8 logs is achieved. However, the
decontaminating effect of Prionzyme (Genencor) is indis-
tinguishable from that of the diluent in which Prionzyme
(Genencor) is prepared (2 M NaOH solution; as per
manufacturer’s instructions) as treatment with 2 M NaOH
alone resulted in no detectable infectivity remaining on the
steel surface (Table 2).
The next most efficient method tested was autoclaving at
134 uC for 18 min in steam permeable autoclave bags [as
stated in the WHO guidelines for prevention of iatrogenic
transmission of vCJD (WHO, 1999)], following which we
detected 0.03 TCIUw units bound to the steel wire imply-
ing 95% of detectable surface-bound prion infectivity is
destroyed (Table 2). Although effective in this instance,
autoclaving has previously been shown to produce highly
variable results depending upon the accessibility of surfaces
to steam (Jackson et al., 2005). Previous studies have also
demonstrated that such a titre of remaining infectivity is
still sufficient to transmit prion disease to laboratory
animals (Taylor et al., 1998; Jackson et al., 2005).
The least effective decontamination reagent of those tested
was HAMO 100 PID (Steris). The HAMO 100 PID reagent
was prepared at 0.8% (v/v) and 1.6% (v/v) (as recom-
mended by the manufacturer) and the remaining infectiv-
ity on the steel surface determined as being equivalent to 13
Fig. 1. PK digestion kinetics of RML- (open circles) and vCJD-
infected brain homogenates (closed circles). Following digestion
with PK for varying times, samples of RML- or vCJD-infected brain
homogenate were subjected to Western blotting and the levels of
PrP immunoreactivity were quantified by densitometry. The values
were then plotted as a percentage of the starting material with
respect to time. Superimposed upon each dataset is a line
representing a fit of the data to a double exponential decay.
Table 1. Both RML- and vCJD-associated PrP displayed
double exponential decays when incubated with a fixed
concentration of PK
RML-infected brain contained the greater proportion of a highly
resistant fraction at 82.7% compared with 60% in vCJD. In addition
to being more abundant, the slowly degraded fraction associated with
RML infection was more resistant to digestion than the equivalent
fraction in vCJD brain, being degraded almost three times slower at
0.0004 s
21 compared with 0.0011 s
21 for vCJD.
RML vCJD
Fast phase amplitude 21.8 46.4
Fast phase rate (s
21) 0.13 0.06
Slow phase
amplitude
82.7 59.6
Slow phase rate (s
21) 0.0004 0.0011
Fig. 2. Comparison of commercial decontamination reagents by
SSBA. Data are shown as the percentage of apparent TCIUW units
remaining on wire after treatment. The ‘% infectivity remaining’ is
calculated as a percentage of the titre of infectivity assayable on
wires exposed to 10
”2 dilution of RML prion-infected brain
homogenate after immersion in PBS for 1 h at room temperature.
Data are presented as mean±SEM. The SEM for autoclaving is zero.
Rely
+On PI, Prionzyme, 2 M NaOH (the carrier for Prionzyme)
decontaminate steel wires to a level beyond detection by the
SSBA and therefore a reduction of prion infectivity of at least
8 logs is achieved.
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bound infectivity, which equates to 0.3 and 0.07 TCIUw
units, respectively. Infected wires which were submerged
into PBS for 1 h at room temperature as a control
displayed no detectable reduction in the titre of prion
infectivity bound (Table 2).
Although exposure of metal-bound prions to very high
temperatures is capable of reducing the titre substantially,
and treatment of such surfaces with 2 M NaOH or 20%
(v/v) sodium hypochlorite has been shown to eliminate
detectable infectivity, these are not methods suitable for
decontaminating delicate and valuable surgical or medical
instruments that incorporate soft metals and plastics and
2 M NaOH is also a highly hazardous solution to facility
operators in a central sterile services department.
End-point titration of RML infectivity bound to
steel surfaces in vivo
To determine the sensitivity of the steel wire bioassay for
RML prions in vivo in tga20 mice, and hence the efficacy of
the decontamination procedures, an end-point titration
was performed. This allowed us to estimate that the
dilution of RML prion-infected brain leading to 1 LD50
wire unit bound is ~10
25.5. Wires exposed to a dilution of
1610
26 of RML prion-infected brain homogenate are
therefore estimated to have the equivalent to 0.3 LD50 wire
units bound. Based on this calculation it can therefore be
extrapolated that a wire exposed to 10
21 dilution of RML-
infected brain can maximally harbour a load of 10
5.5 LD50
intracerebral units per wire. These data are in close
agreement with the findings of Lemmer et al. (2008),
who titred the hamster-adapted scrapie strain Sc237 on
steel wires implanted intracerebrally (i.c.) into hamsters.
These combined data suggest that the limit of detection of
prions bound to steel wires via intracerebral implantation
in rodents is 0.3 LD50 units per wire and is likely to be a
function of the wire surface area.
In vivo analysis of steel wire decontamination by
Rely
+On PI
We then proceeded to further investigate these reagents by
using mouse bioassay of prion-infected wires subjected to
decontamination. As we have previously studied the effect
of autoclaving, have also demonstrated 2 M NaOH to be
effective in mouse bioassay (Jackson et al., 2005), and since
HAMO 100 did not sterilize the wires as assessed by SSBA,
we did not consider it appropriate to study these methods
further in laboratory animals.
Batches of steel wires were exposed to a 10
21 dilution of
RML prion-infected brain [I6200, 10% (w/v) brain homo-
genate containing 10
8.3 LD50 units ml
21] and treated with
Rely
+On PI. Wires were then implanted i.c. into tga20
mice and observed for up to 250 days post-implantation.
No animals were observed to develop any clinical signs of
prion disease and analysis of brain tissue from all these
animals by histology, PrP immunohistochemistry and
Western blotting failed to detect any pathology or abnor-
mal PrP deposition, thereby excluding detectable subclin-
ical infection. It is therefore possible to estimate that
Rely
+On PI reduced the titre of wire bound infectivity by
Table 2. Titration comparisons of RML-infected brain homogenate by standard bioassay, implantation of wires and SSBA
Dilution
of RML brain
Treatment RML prion titre by
Tga20 mouse bioassay
(i.c. LD50 units ml
”1)
RML prion wire titre by
i.c. implantation into Tg20
mice (i.c. LD50 wire units)
TCIUw (estimated by
SSBA) normalized to
1000 cells (mean±SEM)
10
21 None 10
8.3 10
5.5 –
10
22 None 10
7.3 10
4.5 –
10
23 None 10
6.3 10
3.5 –
10
24 None 10
5.3 10
2.5 .3.1
10
25 None 10
4.3 10
1.5 0.57±0.05
10
26* None 10
3.3 10
0.5 0.28±0.02
10
27 None 10
2.3 – 0.15±0.02
10
28D None 10
1.3 2 0.12±0.02
10
29 None – 2 0.04±0.01
10
210 None – 2 0.0029±0.002
10
22 Rely
+On PI – ,10
0.5 ,0.0029
10
22 HAMO 100 (0.8% v/v) – 2 0.2963
10
22 HAMO 100 (1.6% v/v) – 2 0.0725
10
22 Prionzyme – 2 ,0.0029
10
22 2 M NaOH – 2 ,0.0029
10
22 Autoclave at 134 uC– 2 0.0325
*Limit of detection of RML prion infectivity in tga20 by wire i.c. inoculation.
DLimit of detection of RML prion infectivity in tga20 by conventional i.c. inoculation of brain homogenate.
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infectivity remained it was below the detection limit of the
bioassay (Table 3). These data support the findings of the
SSBA and exclude the possibility that the decontaminating
reagent merely altered the strain properties of RML prions,
rendering them undetectable by the N2aPK1 cells (Klohn
et al., 2003) used in the cell-based SSBA.
DISCUSSION
It is well documented that prions bind avidly to many
surfaces, in particular stainless-steel (Zobeley et al., 1999;
Flechsig et al., 2001). This fact, coupled to the unusually
high resistance of prions to standard decontamination
methods, the widespread tissue distribution of infectivity
(Wadsworth et al., 2001; Bruce et al., 2001; Wadsworth
et al., 2007) and uncertain population prevalence of vCJD
prion infection, leaves ongoing public health concerns
about iatrogenic transmission of vCJD prion infection in
the hospital setting. Recent epidemiological evidence
suggesting a proportion of apparently ‘sporadic’ or classical
CJD may be linked to general surgery is exacerbating these
concerns (Collins et al., 1999; Mahillo-Fernandez et al.,
2008; de Pedro-Cuesta et al., 2010). In response to such
concerns, much publically funded research was performed
in the UK and elsewhere and a variety of companies have
invested in the development of prion decontamination
reagents. Here, we have exploited the highly sensitive SSBA
(Edgeworth et al., 2009), developed for the quantitative
analysis of prions bound to steel surfaces, to compare
commercially available decontamination reagents directly.
By end-point titration of RML prion-infected brain
homogenate on steel wires i.c. implanted into tga20
indicator mice, we have estimated the maximal loading
capacity of a 5 mm (USP 4/0) steel wire as being 10
5.5 LD50
units (Table 3), which limits the sensitivity of bioassay
using rodents. Our findings are in close agreement with the
results of Lemmer et al. (2008), who used a distinct prion
strain, hamster scrapie-adapted Sc237, on i.c. implanted
wires and also concluded the maximal loading capacity of
wires i.c. implanted to be 10
5.5 LD50 units. This therefore
suggests the detection limit for prion infectivity presented
on steel wires may be independent of prion strain to which
the wires have been exposed.
The SSBA used here for the comparison of commercially
available prion decontamination reagents is capable of
detecting infectivity, resulting from exposure of steel wires
to a sample containing 0.025 LD50 units ml
21 of RML
compared with mouse bioassay where the limit of detection
is ~2500 LD50 units ml
21 (Table 2). The SSBA allows
assessment of decontamination over a ~8 log range.
The WHO recommended protocols for the control for
iatrogenic transmission of prions that include: immersion
in freshly prepared 1 M NaOH, or NaOCl, at a concen-
tration exceeding 20000 p.p.m. available chlorine, for 1 h
at 20 uC, or porous load autoclaving at 134 uC for 18 min
(WHO, 1999). However, autoclaving is not always an
effective method for the decontamination of prion-infected
surgical steel instruments (Taylor et al., 1998; Jackson et al.,
2005) due to the variable ingress of superheated steam and
the use of 2 M NaOH or NaOCl are not viable options for
devices containing soft metals, rubbers and plastics, and are
hazardous to staff. Here, we demonstrate that steel
contaminated with RML prions can still harbour 5% of
contaminating infectivity after autoclaving at 134 uC for
18 min. This level of bound infectivity is still sufficient to
Table 3. Bioassay data from tga20 mice inoculated i.c. with 5 mm Steelex monofilament wires (USP4/0), exposed to a serial dilution
of RML-infected brain homogenate
Animals inoculated with wires treated with Rely
+On PI (as described in Methods) survived to the end point of the experiment (.250 days post-
inoculation). Subsequent Western blot and immunohistochemistry (IHC) analysis confirmed no signs of subclinical infection.
Dilution of RML brain Treatment of wires prior to
inoculation
Animals affected*D/totald Mean incubation period
(days±SEM)
10
21 None 20/20 76±1
10
22 None 18/18 86±2
10
23 None 18/18 85±2
10
24 None 18/18 113±9
10
25 None 28/35 114±7
10
26 None 4/18 157±24
10
27 None 0/19 .250
10
28 None 0/20 .250
PBS control None 0/20 .250
10
21 Rely
+On PI 0/19 .250
*All clinically affected animals were confirmed prion-infected by Western blot and IHC analysis for the presence of PrP
Sc.
DClinically unaffected animals showed no signs of subclinical infection by Western blot or IHC analysis.
dVariation in experimental group sizes due to intermittent losses for health reasons other than prion infection.
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indicator mice (Jackson et al., 2005) and may still pose a
risk of iatrogenic transmission in a hospital setting.
The least effective reagent for prion decontamination tested
in this study was the alkali/detergent reagent HAMO 100
PID. This commercial product when tested at both the
recommended (0.8% v/v) and twice the recommended
concentration (1.6% v/v) failed to thoroughly decontam-
inate the steel wire surfaces, leaving 13 and 0.4% of
maximally detectable infectivity on the wires.
The most effective of the prion decontamination reagents
tested were the proteolytic reagents Rely
+On PI (DuPont
Corporation) and Prionzyme (Genencor). Both reagents
decontaminatedthewirescontaminatedwithRMLprionsto
beyond the detection limit of the SSBA. The manufacturers
of Prionzyme (Genencor) recommend preparation of the
reagentin 2 M NaOH alkalicarrier,whichalonereducedthe
titre of infectivity bound to steel surfaces beyond the
detection limit of the SSBA. This made it impossible to
determine if the Prionzyme had an effect in addition to that
of the 2 M NaOH in which it had been prepared (Table 2).
The preparation of Prionzyme in 2 M NaOH also calls into
question how practical its use would be.
A persistent problem in establishing the relative efficacy of
methods for prion decontamination has been the absence
of a sensitive and relevant assay that can be used as a
standard for comparison. This study has evaluated several
novel commercially available reagents as well as established
methods of decontamination under comparable conditions
in an extremely sensitive cell culture-based assay. Each of
these decontamination reagents are claimed by their
manufacturers to reduce prion infectivity by several logs
to beyond the detection method used. However, the
validation of each of these reagents has been performed
using different methodologies, making direct comparison
of published results difficult. The different methods have
encompassed various prion strains [all of which have
different proteolytic and thermodynamic properties
(Somerville et al., 2002)], assays with variable detection
limits, and different starting materials used to provide the
prion infectivity (macerates, homogenates or steel bound).
While it has been suggested that the mouse-adapted BSE
strain 301V may be a more suitable model to study vCJD
prion inactivation (SEAC, 2006), passage of a prion strain
in a new species may unpredictably affect its physico-
chemical properties and indeed this has recently been
shown to be the case with 301V, which differs markedly in
its inactivation properties to cattle BSE (Giles et al., 2008).
In order to assess and validate enzymic approaches to prion
decontamination the selection of a suitable prion strain is
crucial. The use of RML-infected material as a model
substrate offers the advantage of containing material with
greater resistance to proteolysis than vCJD material, which
is also present in greater proportion.
This study provides a standardized method by which to
compare the efficacy of reagents and methods for the
decontamination of surgical instruments and offers an
assay with a high dynamic range and sensitivity, beyond
that of conventional rodent bioassay.
METHODS
Kinetic analysis of PK digestion of RML and vCJD brain
homogenates. RML and vCJD prion-infected brain homogenates
(10%, w/v) were clarified by centrifugation at 80 g for 1 min.
Supernatants were removed and pre-warmed to 37 uC for 10 min.
Aliquots (20 ml) were removed and mixed with an equal volume of 26
SDS loading buffer [Tris-HCL, 20% (v/v) glycerol pH 6.8 containing
4% (w/v) SDS, 4% (v/v) 2-mercaptoethanol, 8 mM 4-(2-aminoethyl)-
benzonase sulfonyl fluoride and 0.02% (w/v) bromophenol blue] and
snap frozen in liquid nitrogen, time point 0. PK (BDH) was added to
remaining homogenates to a final concentration of 50 mgm l
21.
Samples were incubated with agitation at 37 uC from which 20 ml
aliquots were removed after 2, 5, 10, 15, 20, 30, 40, 60, 80, 120, 160, 200
and 240 min and treated as before. Samples were analysed by Western
blottingasdescribedpreviously (Wadsworthetal.,2001) usingprimary
antibody ICSM 35 at 0.2 mgm l
21 in PBS/1% Tween-20 (PBST). Total
PK-resistant PrP was determined using densitometry.
Culturing and storage of N2aPK1 cells. The N2aPK1 cell-line
that is highly susceptible to infection with the RML prion strain
(Klohn et al., 2003) was used throughout the study. Cells were
cultured in Opti-MEM-10% FCS and 1% penicillin/streptomycin
(OFCS) (Invitrogen).
Individual vials containing 3 million cells of expanded subclones of
the N2aPK1 cells were thawed from stocks kept in liquid nitrogen in
OFCS and 6% (v/v) DMSO and cultured for 10 days prior to
incubation with RML-coated wires. Cells were cultured for no more
than four passages prior to use in the SSBA (Edgeworth et al., 2009) as
prolonged subculturing leads to reduced susceptibility to infection.
Preparation of homogenates. Non-infected mouse brain homo-
genateswerepreparedfromPrnp
0/0mice(Bueleretal.,1993),whichhad
been back-crossed onto an FVB/NHsd background (Asante et al.,2 0 0 9 )
as 20% (w/v) in PBS by passing through 21G to 26.5 G needles
successively. Homogenatewas storedas20 ml aliquots at280 uC. RML-
infected brain homogenate (designated inocula number I6200) was
prepared and titred as described previously (Cronier et al., 2008). I6200
has a titre of 10
8.3 LD50 units ml
21 of 10% (w/v) brain homogenate.
Preparation of steel wires for cell-based assay. Steelex monofila-
ment wires, USP 4/0 were cut to 2.5 cm lengths for cell-culture or
5 mm lengths for bioassay. Batches of 100 wires were placed into 50 ml
falcon tubes containing 20 ml 2% (v/v) Triton X-100 in deionized
water. Wires were washed on a rocking platform for 2 h at room
temperature and then washed for 5615 min in 50 ml deionized water.
Wires were then sterilized in 70% (v/v) ethanol in deionized water for
10 min and air-dried in a class 2 microbiological safety cabinet.
Coating of steel wires and SSBA. Wires were placed into 1 ml
Eppendorf tubes containing 1 ml inocula I6200 [10
8.3 LD50 units
ml
21 10% (w/v) brain homogenate] serially diluted into 10
24 Prnp
0/0
brain homogenate prepared in Opti-MEM/10% (v/v) FCS. Steelex
monofilament wire segments (60 segments of 2.5 cm) were gently
agitated for 30 s and then incubated with the required RML brain
homogenate dilution for 2 h at room temperature. Wires were
washed in PBS containing 1% penicillin/streptomycin for 5615 min
on a rotary wheel, air-dried and placed at a maximum of 20 wires per
well into separate wells of a six-well tissue culture plate (Corning) and
covered with 300000 N2aPK1 cells. SSBA was performed as described
previously (Edgeworth et al., 2009).
Comparison of commercial prion decontamination reagents
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exposed to a logarithmic dilution series (10
23–10
29) of I6200 in 10
24
FVB/N-Prnp
0/0 brain homogenate for 2 h and assayed by the SSBA as
described previously (Edgeworth et al., 2009). Batches of wires for
decontaminationwereexposedto1 ml10
21 dilutionofI6200prepared
as above. Wires were immersed into decontamination solutions, which
were freshly prepared and used as directed by the manufacturer.
Prionzyme (Genencor) was prepared as 2% (v/v) in 2 M NaOH
(pH 12) and wires were incubated for 30 min at 60 uC.
HAMO 100 Prion Inactivating Detergent (HPID; Steris) was prepared
at either 0.8% (v/v) (recommended concentration by manufacturer)
or 1.6% (v/v) in deionized water and wires were incubated at 43 uC
for 15 min.
Rely
+On PI (DuPont Corporation) was prepared as a 56 stock by
mixing 4.05 g pack A+2.5 g pack B+0.4 g pack C in a total volume
of 50 ml of 50 uC deionized water for 10 min. Stock was then diluted
to 16 working solution in deionized water in which wires were
incubated in decontamination solution for 10 min at 50 uC.
For comparison, infected wires were decontaminated by autoclaving
at 134 uC for 18 min in steam permeable bags or submerged into 2 M
NaOH for 30 min at 20 uC. As a negative control, infected wires were
immersed into PBS for 1 h at room temperature.
Wires were then rinsed in PBS at room temperature and dried before
exposure to N2aPK1 cells. Cells were harvested from wires after a
3 day exposure, seeded at 4000 cells per well and assayed by SSBA
(Edgeworth et al., 2009), using 16 replica wells per sample.
Mouse bioassay of RML prion-infected wires. Steelex monofila-
ment wire segments(60 segmentsof 5 mm) were prepared as described
above for the SSBA. Wires were inserted i.c. into groups of tga20 mice
(Fischer et al., 1996) as described previously (Flechsig et al., 2001).
Wires used for testing the decontamination reagent Rely
+On PI (Du
Pont Corporation), unlike those used for the dilution series, were not
rinsed in PBS prior to exposure to the decontamination reagent so as
to provide a more stringent test of decontamination. Wires were
exposed to Rely
+On PI for 10 min at 50 uC according to the
manufacturer’s instructions. Briefly, rinsed in PBS to remove residual
decontamination reagent, air-dried, and then inserted i.c. into a
group of 20 tga20 mice.
Estimation of LD50 units on wires. This was as described previously
(Edgeworth et al., 2009); briefly, the mean number of tissue culture
infectious units (TCIU) per well, m, is calculated using the Poisson
distribution according to the equation:
P(0)5e
2m
where P(0) is the number of non-infected wells/total number of wells.
The value of m as determined by the wire (w) assay under standard
assay conditions (TCIUw per well) can be translated into apparent
LD50 units on wire (where one LD50 unit represents the dose that
would be lethal to 50% of animals inoculated by the intracerebral
route) by exposing wires to serial dilutions of a brain homogenate
that has previously been titrated by intracerebral injection into wild-
type mice, and plotting the resulting m values against the logarithm of
the LD50 units on wire.
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